A phase 1/2 trial of Amplimexon (Imexon, Inj.) plus dacarbazine (DTIC) in chemotherapy naive patients with unresectable stage III or stage IV malignant melanoma

Trial Profile

A phase 1/2 trial of Amplimexon (Imexon, Inj.) plus dacarbazine (DTIC) in chemotherapy naive patients with unresectable stage III or stage IV malignant melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2010

At a glance

  • Drugs Dacarbazine; Imexon
  • Indications Malignant melanoma
  • Focus Adverse reactions; Biomarker
  • Sponsors AmpliMed
  • Most Recent Events

    • 06 Jun 2008 Final results presented at the American Society of Clinical Oncology (ASCO) 2008 annual meeting.
    • 13 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 09 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top